Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
Abroad (travel likely)RecruitingPHASE1
Conditions
Schizophrenia · Schizo-Affective Disorder · Schizophreniform; Schizophrenic · Bipolar Disorder I · Bipolar Disorder II
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
BioXcel Clinical Research Site, Anaheim, California, United States
Bioxcel Clinical Research Site, Hialeah, Florida, United States
BioXcel Clinical Research Site, Atlanta, Georgia, United States
Bioxcel Clinical Research Site, Decatur, Georgia, United States
BioXcel Clinical Research Site, DeSoto, Texas, United States
Study leads
Robert Risinger, MD
Study Chair
BioXcel Therapeutics